Canada markets close in 51 minutes

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3794-0.0106 (-2.73%)
As of 2:50PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.3900
Open0.3800
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3725 - 0.4000
52 Week Range0.2600 - 0.7000
Volume1,236,895
Avg. Volume2,955,796
Market Cap99.336M
Beta (5Y Monthly)0.12
PE Ratio (TTM)N/A
EPS (TTM)-0.0500
Earnings DateMay 27, 2021 - May 31, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Revive Adjourns Annual and Special Meeting
    GlobeNewswire

    Revive Adjourns Annual and Special Meeting

    TORONTO, April 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces that its Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021 will be adjourned to a future date. Due to the current provincial lockdown in response to the COVID-19 pandemic, the Meeting was to be held by way of conference call. Due to the high shareholder turnout and interest, the service provider contracted to arrange the conference call experienced technical difficulties with the bridge facilities. In order to ensure that all shareholders are able to attend and participate at the Meeting, the Company has decided to adjourn the Meeting in order to procure enhanced conference facilities. A subsequent press release will be disseminated with the updated call-in information. About Revive Therapeutics Ltd. Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com. For more information please contact: Michael FrankChief Executive OfficerRevive Therapeutics Ltd. Tel:1 888 901 0036Email:mfrank@revivethera.com Website:www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

  • CEO Presenting on the Emerging Growth Conference on April 14; Register now
    GlobeNewswire

    CEO Presenting on the Emerging Growth Conference on April 14; Register now

    Niche Companies in Therapeutics, Energy, Defense and more in AttendanceMIAMI, April 12, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies announces the Schedule of the 5th Emerging Growth Conference. EmergingGrowth.com is proud to present and welcome you to the 5th Emerging Growth Conference. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. The schedule for March 31st from 9:30 AM until 4:00 PM is as follows: (All times are Eastern Time Zone) We may see some schedule changes on Wednesday. To stay current on the schedule, please follow us on Twitter: https://twitter.com/EmergingGrowthC 9:00 – 9:45Vivos Therapeutics Inc. (NASDAQ: VVOS) Kirk Huntsman, CEO Brad Amman, CFO Edward Lowe, IRP 9:45 – 10:30Revive Therapeutics, (OTC Pink: RVVTF) Michael Frank, President & CEO Derrick Welsh, COO 10:30 - 11:15Lobe Sciences (OTC Pink: GTSIF) (CSE: LOBE) Phillip Young, CEO 11:15 – 12:00AMMO, Inc. (NASDAQ: POWW) Chris Larson, Founder 12:00 – 12:30Foothills Exploration, Inc. (OTC: FTXP) Chris Jarvis, Executive VP 12:30 - 1:15Xtreme Fighting Championships, Inc. (OTC Pink: DKMR) Steve Smith, CEO Myron Molotky, President 1:15 - 2:00Ur-Energy (NYSE American: URG) (TSX: URE) Jeffrey Klenda, Chairman & CEO 2:00 - 2:30International Consolidated Companies, Inc. (OTC Pink: INCC) Antonio Uccello, CEO 2:30 – 3:00PHI Group, Inc. (OTC Pink: PHIL) Henry Fahman, Chairman & CEO 3:00 - 3:30Enzolytics, Inc. (OTC Pink: ENZC) Charles Cotropia, CEO 3:30 - 4:00First Graphene Ltd. (OTC Pink: FGPHF) (ASX: FGR) Warwick Grigor, Chairman All interested in attending should visit the following link to register. You will then receive an email containing the link and time to sign into the conference. Register for the conference here. We may see some schedule changes on Wednesday. To stay current on the schedule, please follow us on Twitter: https://twitter.com/EmergingGrowthC These exciting virtual conferences are like attending an “in person” event, you can sign in and out as often as you like. About EmergingGrowth.comFounded in 2009, Emerging Growth.com quickly became a leading independent small cap media portal. Over the years, it has developed an extensive history of providing unparalleled content, in identifying emerging growth companies and markets that can be overlooked by the investment community. The next step in its evolution is the Emerging Growth Conference. About the Emerging Growth ConferenceThe Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in an effective and time efficient manner. The Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. The audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. Thanks for participating and make sure you to follow us on Twitter and YouTube to be the first to hear updates on the Conference and when the Conferences are available for replay. All Conferences are first announced on Twitter – Follow us on Twitter All Conference replays emerge on our YouTube Channel – Subscribe to our YouTube Channel All sessions will be conducted through video webcasts and will take place in the Eastern time zone. Provided above is the current Emerging Growth Conference schedule for featured presentations. Each company’s presentations will be delivered by their executive management team. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com. If you believe your company, product or service is at the cusp of going mainstream, or you have an idea for an “Emerging Growth” company that might fit our model, contact us here. Thank you for your interest in our conference, and we look forward to your participation in future conferences. Contact: Emerging Growth Phone: 1-305-330-1985Email: Conference@EmergingGrowth.com

  • Revive Provides Dial-In Information for Annual and Special Meeting
    GlobeNewswire

    Revive Provides Dial-In Information for Annual and Special Meeting

    TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign. In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders. About Revive Therapeutics Ltd. Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com. For more information please contact: Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel: 1 888 901 0036Email: mfrank@revivethera.comWebsite: www.revivethera.com Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.